Search Results for “EC” – Page 354 – media

Novartis Launches Sandoz Spinoff, Creating Independent Company

Separate entity allows company to concentrate on status as focused medicines company. Image Credit: Adobe Stock Images/Livinskiy Novartis has officially completed the spinoff process for Sandoz, its generics and biosimilars division, with each shareholder receiving one Sandoz share for every five Novartis shares or one Sandoz American Depositary Receipt (ADR) for every five Novartis ADRs. In the future, Novartis intends to become solely a focused medicines company. “This is a truly historic moment for Novartis and Sandoz, as we begin new chapters as independent companies. With several consecutive quarters of sales growth, Sandoz starts out from a position of strength as a global leader in Generics and Biosimilars, and I am confident they are poised to deepen their impact on patients and society,” said Vas Narasimhan, MD, CEO, Novartis. “Today, after more than USD 100bn in transactions over the last few years, Novartis emerges as a fully focused innovative medicines ...
- Source: drugdu
- 186
- October 7, 2023
ICHRAs Are Gaining Steam, But Employers are Still Out of the Know

ICHRAs provide employees with more choice on their health benefits. But many employers aren’t very familiar with the new insurance model, executives say. By MARISSA PLESCIA More employers are turning to Individual Coverage Health Reimbursement Arrangements (ICHRAs): the number of employers who adopted ICHRAs increased by 64% between 2022 and 2023, according to the HRA Council. Still, many employers aren’t super familiar with the model, industry experts say. ICHRAs first became available in 2020 and are an alternative to traditional group plans. They allow employers of any size — though smaller employers may particularly be interested — to provide a tax-free reimbursement to their employees so they can shop for a health plan of their choice, including through the individual ACA market on state exchanges. The amount employees are reimbursed varies based on several factors, such as age, family size or where they live. “This allows you as an employee ...
- Source: drugdu
- 195
- October 7, 2023
Lumicell co-founder wins Nobel Prize in Chemistry

The co-founder of a fluorescence-guided imaging technology firm has been awarded part of the Nobel Prize in Chemistry in acknowledgement of his research into quantum dots. The Nobel Prize Committee said that Moungi Bawendi revolutionised the chemical production of quantum dots, resulting in almost perfect particles. Quantum dots are nanoparticles so tiny that their size determines their properties. They have frequently been employed in the use of medical imaging devices such as those provided by the company Bawendi co-founded, Lumicell. The Nobel Prize Committee said: “Quantum dots now illuminate computer monitors and television screens based on QLED technology. They also add nuance to the light of some LED lamps, and biochemists and doctors use them to map biological tissue.” The Royal Swedish Academy of Sciences additionally awarded the prize to two other researchers, Louis E. Brus and Alexei I. Ekimov. Both of whom were pivotal in the development of quantum ...
- Source: drugdu
- 133
- October 7, 2023
backAgomab’s FSCD therapy gains fast track designation from US FDA

Agomab Therapeutics has received the US Food and Drug Administration (FDA)’s fast track designation for AGMB-129 to treat fibrostenosing Crohn’s disease (FSCD). Designed to inhibit ALK5 in the gastrointestinal (GI) tract, AGMB-129 is an oral, small molecule GI-restricted ALK5 (TGF-βRI) inhibitor currently in clinical development. The single and multiple-dose AGMB-129 was well-tolerated at all doses in a Phase I study in healthy participants. The company has also announced the commencement of the STENOVA Phase IIa clinical study to assess AGMB-129 for patients with symptomatic FSCD. This global, placebo-controlled, multi-centre, double-blind study will assess 36 patients with symptomatic FSCD at investigational sites in Europe, Canada and the US. Subjects will be randomised to receive one of two doses of AGMB-129 or a placebo for a period of 12 weeks. Tolerability and safety of AGMB-129 in FSCD patients are the primary endpoints of the trial. The pharmacokinetics and target engagement at the ...
- Source: drugdu
- 102
- October 7, 2023
What Pharma Fears Most About AI

As artificial intelligence (AI) hovers between a “buzz phrase” and marveled reality, many point to the potential the technology has in the pharma industry. While some criticize the rate at which pharma uptakes new technologies and implements them into their processes, the industry must also strike a fine balance with moving cautiously when it comes to changes due to the nature of the industry and the potential impact on patients those changes can bring. But it can’t be denied that there is a plethora of data in every part of the process of drug creation and distribution that needs to be more efficiently managed and utilized—from preclinical and R&D to manufacturing to commercialization and distribution. But perhaps one of the greatest appeals of AI is the potential it has for innovation. Andrew Hopkins, founder and CEO of Exscientia, an AI-driven precision medicine company founded in 2012, shares in this Q&A ...
- Source: drugdu
- 120
- October 6, 2023
Already Partnered With Nvidia and Eli Lilly, Iambic Adds $100M for AI Drug Discovery

Iambic Therapeutics brings together software engineers and drug-hunting scientists, all sharing the goal of using artificial intelligence to optimize properties of small molecule drugs. The startup will apply its Series B financing to a cancer drug pipeline that includes two candidates on track for the clinic in 2024. By FRANK VINLUAN Drug discovery isn’t only about finding new targets. There’s still plenty of opportunity to find better ways to hit targets that are already drugged, according to Tom Miller, CEO of startup Iambic Therapeutics. Understanding how a molecule interacts with a known disease target enables drug hunters to design molecules that could be superior alternatives for patients. Miller notes that a molecule’s ability to bind to a target protein while leaving related proteins unaffected improves its safety. It’s also important to understand how the distribution of a molecule across tissues in the body affect efficacy. Iambic’s drug discovery research employs ...
- Source: drugdu
- 221
- October 6, 2023
Syneos Health Appoints Colin Shannon as CEO

Exec joins the organization with decades of biopharma experience. Image Credit: Adobe Stock Images/Mongkol Syneos Health, a biopharma clinical and commercial solutions organization has appointed Colin Shannon as CEO, effective immediately. He succeeds Michelle Keefe, who will continue her tenure with Syneos Health as a member of the executive leadership team. Shannon and Keefe will remain on the board of directors. Shannon brings decades of leadership experience driving growth at global biopharmaceutical solutions organizations. During his 14 years at PRA Health Sciences, he served in executive roles, most recently as chairman and CEO. During his tenure, he led the company through a successful IPO and subsequent sale to ICON plc., where he also served on its board of directors. “It is an honor to be tasked with leading Syneos Health at such an exciting time in its evolution,” comments Shannon. “I look forward to working with Michelle and the rest ...
- Source: drugdu
- 170
- October 6, 2023
Research could lead to the development of new weight-loss drug that mimics exercise

A brand-new kind of drug, tested in mice, shows promising new results that could lead to the development of a new weight-loss drug that mimics exercise. The new compound, developed and tested by a University of Florida professor of pharmacy and his colleagues, leads obese mice to lose weight by convincing the body’s muscles that they are exercising more than they really are, boosting the animals’ metabolism. It also increases endurance, helping mice run nearly 50% further than they could before. All without the mice lifting a paw. The drug belongs to a class known as “exercise mimetics,” which provide some of the benefits of exercise without increasing physical activity. The new treatment is in the early stages of development but could one day be tested in people to treat diseases like obesity, diabetes, and age-related muscle loss. The research comes as drugs like Ozempic have provided a breakthrough in ...
- Source: drugdu
- 203
- October 6, 2023
New Alzheimer’s disease medication approved in Japan

Eisai and BioArctic have received approval for the Alzheimer’s disease drug Leqembi (lecanemab-irmb) in Japan, making it the second country to gain access to the treatment. Leqembi is a monoclonal antibody that targets and reduces insoluble amyloid-beta (Aβ) forms in the brain. It is the first and only approved treatment that has demonstrated a reduction in the rate of disease progression in patients with Alzheimer’s. The Japanese approval unlocked a milestone-based payment of EUR 17m ($18m) to BioArctic. The approval is based on Phase III data from the Clarity AD trial (NCT03887455) led by Eisai that showed that treatment with Leqembi reduced clinical decline in patients by 27% at 18 months compared to the placebo. The prescribing information for Leqembi includes a warning for amyloid-related imaging abnormalities (ARIAs), a concern for Alzheimer’s patients taking certain medication. Last week, BrainScope announced an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to ...
- Source: drugdu
- 103
- October 6, 2023
Novo Nordisk Foundation commits €127m for new cell therapy facility

The Novo Nordisk Foundation has announced that it has committed up to €127m in funding to develop and manufacture a new cell therapy facility, Cellerator, in Denmark, to help fight chronic diseases. The new Novo Nordisk Foundation, Cellerator, will be used for the final development steps of animal research and upscaling new cell therapies for testing in humans. This will help to accelerate treatments for people with diseases including chronic heart failure, Parkinson’s disease, kidney disease, type 1 diabetes and several forms of cancer. Cell therapies work by transplanting living cells into patients to treat diseases. It’s estimated that one in three adults suffers from multiple chronic conditions. In the US alone, it’s been calculated that out of 58 million deaths in 2005, chronic disease was responsible for 35 million. The funding follows a report prepared for the European Federation of Pharmaceutical Industries and Associations, which came to the conclusion ...
- Source: drugdu
- 104
- October 6, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.